Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Despite the various research efforts toward the treatment of stress-related disorders, the drug has not yet launched last 20 years. Corticotropin releasing factor-1 receptor antagonists have been point of great interest in stress-related disorders. In the present study, we have selected benzazole scaffold-based compounds as corticotropin releasing factor-1 antagonists and performed 2D and 3D QSAR studies to identify the structural features to elucidating the binding mechanism prediction. The best 2D QSAR model was obtained through multiple linear regression method with r value of .7390, q value of .5136 and pred_r (predicted square correlation coefficient) value of .88. The contribution of 2D descriptor, T_2_C_1 was 60% (negative contribution) and 4pathClusterCount was 40.24% (positive contribution) in enhancing the activity. Also 3D QSAR model was statistically significant with q value of .9419 and q_se (standard error of internal validation) value of .19. Statistical parameters results prove the robustness and significance of both models. Further, molecular docking and pharmacokinetic analysis was performed to explore the scope of investigation. Docking results revealed that the all benzazole compounds show hydrogen bonding with residue Asn283 and having same hydrophobic pocket (Phe286, Leu213, Ile290, Leu287, Phe207, Arg165, Leu323, Tyr327, Phe284, and Met206). Compound B14 has higher activity compare to reference molecules. Most of the compounds were found within acceptable range for pharmacokinetic parameters. This work provides the extremely useful leads for structural substituents essential for benzimidazole moiety to exhibit antagonistic activity against corticotropin releasing factor-1 receptors.

Download full-text PDF

Source
http://dx.doi.org/10.1080/07391102.2017.1332688DOI Listing

Publication Analysis

Top Keywords

corticotropin releasing
16
releasing factor-1
16
binding mechanism
8
mechanism prediction
8
factor-1 receptor
8
receptor antagonists
8
molecular docking
8
docking pharmacokinetic
8
pharmacokinetic parameters
8
stress-related disorders
8

Similar Publications

Pelvic visceromotor functions such as micturition are regulated by coordinated autonomic and somatic motor pathways from the central nervous system. The parasympathetic system induces detrusor muscle contraction while the somatic system facilitates relaxation of the external urethral sphincter, ensuring synchronized and efficient bladder emptying during the voiding process. This study explores the relationship between Barrington's nucleus corticotropin-releasing hormone (CRH)-ergic projections and the formation of perineural nets (PNNs) among spinal motoneurons, particularly parasympathetic preganglionic neurons in the intermediolateral nucleus (IML) and Onuf's nucleus during the maturation of the neural circuitry controlling pelvic visceromotor functions.

View Article and Find Full Text PDF

Insulin tolerance tests (ITTs), glucagon tests, and low or standard-dose adrenocorticotropic hormone tests are used to evaluate the hypothalamic-pituitary-adrenal (HPA) axis. While ITT is considered the gold standard test for stimulating both the cortisol and growth hormone axis, its use in young children carries a risk of hypoglycemia, making it potentially unsafe. Recent studies indicate that L-dopa stimulates the release of adrenocorticotropic hormone and cortisol.

View Article and Find Full Text PDF

Corticotropin-Releasing Hormone in Melanoma and Nonmelanoma Skin Cancer.

J Skin Cancer

August 2025

Department of Dermatology, University Medical Center Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, Germany.

Corticotropin-releasing hormone (CRH) regulates immunological and cellular processes. Recently, CRH is expressed in skin cancers, where its expression appears to correlate with the degree of malignancy. This study correlates CRH expression in melanoma metastases with patient survival and compares the intensity of CRH expression in melanoma to that in less aggressive skin cancer entities.

View Article and Find Full Text PDF

Introduction: Ectopic adrenocorticotropic hormone (ACTH)/corticotropin-releasing hormone production by tumours causes 5-10% of Cushing's syndrome cases. We present a 21-patient case series with ectopic Cushing's syndrome (ECS) from a tertiary care institute in India.

Methods: Data were collected retrospectively for patients from 1984 to 2004 and prospectively thereafter till 2019.

View Article and Find Full Text PDF

Heterozygous loss-of-function mutations are one established cause of isolated dystonia and hyposmia. Homozygous mutations have been reported in siblings with generalized dystonia and intellectual disability. encodes major [NM_001369387.

View Article and Find Full Text PDF